The FDA’s Center for Drug Evaluation says it found low levels of NDMA, a probable human carcinogen in ranitidine medicines, including some OTC Zantac brand products. NDMA is dangerous when consumed in large quantities, but the FDA says the levels found in H2 blockers don’t pose a risk. This HBW story looks at similar probes by the European Medicines Authority, NDMA levels in other drugs, and statements by the FDA that while there is no recall in place, consumers should consider alternatives as multiple drugs are approved for the same or similar use.